PE20190623A1 - Formas solidas cristalinas de un inhibidor de bet - Google Patents
Formas solidas cristalinas de un inhibidor de betInfo
- Publication number
- PE20190623A1 PE20190623A1 PE2018003269A PE2018003269A PE20190623A1 PE 20190623 A1 PE20190623 A1 PE 20190623A1 PE 2018003269 A PE2018003269 A PE 2018003269A PE 2018003269 A PE2018003269 A PE 2018003269A PE 20190623 A1 PE20190623 A1 PE 20190623A1
- Authority
- PE
- Peru
- Prior art keywords
- crystal forms
- solid crystal
- xrpd
- refers
- whose
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- 229940125763 bromodomain inhibitor Drugs 0.000 title 1
- 239000000843 powder Substances 0.000 abstract 2
- 108091005625 BRD4 Proteins 0.000 abstract 1
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 abstract 1
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 abstract 1
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 abstract 1
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 abstract 1
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01M—CATCHING, TRAPPING OR SCARING OF ANIMALS; APPARATUS FOR THE DESTRUCTION OF NOXIOUS ANIMALS OR NOXIOUS PLANTS
- A01M31/00—Hunting appliances
- A01M31/06—Decoys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
Abstract
SE REFIERE A FORMAS SOLIDAS CRISTALINAS DEL COMPUESTO DE FORMULA (I) QUE ES 2,2,4-TRIMETIL-8-(6-METIL-7-OXO-6,7-DIHIDRO-1H-PIRROLO[2,3-C]PIRIDIN-4-IL)-6-(METILSULFONIL)-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONA, TALES COMO A) LA FORMA I CUYO PATRON DE DIFRACCION EN POLVO DE RAYOS X (XRPD) EN ANGULO 2THETA TIENE LOS SIGUIENTES PICOS: 8.7, 9.8, 11.6, 12.7, 14.7, 15.7, 20.0, 21.4, 23.3 Y 27.1 GRADOS; Y B) LA FORMA II CUYO PATRON DE DIFRACCION EN POLVO DE RAYOS X (XRPD) EN ANGULO 2THETA TIENE LOS SIGUIENTES PICOS: 6.7, 9.5, 10.5, 14.8, 16.2, 17.0, 18.8 Y 19.3 GRADOS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION. DICHO COMPUESTO DE FORMULA (I) ES UN INHIBIDOR DE PROTEINAS BET TALES COMO BRD2, BRD3, BRD4 Y BRD-t, SIENDO UTIL PARA EL TRATAMIENTO DE CANCER
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662352220P | 2016-06-20 | 2016-06-20 | |
US201662397575P | 2016-09-21 | 2016-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20190623A1 true PE20190623A1 (es) | 2019-04-26 |
Family
ID=59258384
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023002468A PE20240236A1 (es) | 2016-06-20 | 2017-06-19 | Formas solidas cristalinas de un inhibidor de bet |
PE2018003269A PE20190623A1 (es) | 2016-06-20 | 2017-06-19 | Formas solidas cristalinas de un inhibidor de bet |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023002468A PE20240236A1 (es) | 2016-06-20 | 2017-06-19 | Formas solidas cristalinas de un inhibidor de bet |
Country Status (32)
Country | Link |
---|---|
US (5) | US10189832B2 (es) |
EP (2) | EP3472157B1 (es) |
JP (4) | JP7096170B2 (es) |
KR (3) | KR102643344B1 (es) |
CN (3) | CN114369091A (es) |
AU (3) | AU2017281286B2 (es) |
BR (1) | BR112018076486A2 (es) |
CA (3) | CA3028689A1 (es) |
CL (3) | CL2018003702A1 (es) |
CO (1) | CO2018014339A2 (es) |
CR (2) | CR20220651A (es) |
CY (1) | CY1126092T1 (es) |
DK (1) | DK3472157T3 (es) |
EC (1) | ECSP19001982A (es) |
ES (1) | ES2945063T3 (es) |
FI (1) | FI3472157T3 (es) |
HR (1) | HRP20230466T1 (es) |
HU (1) | HUE062234T2 (es) |
IL (3) | IL263824B2 (es) |
LT (1) | LT3472157T (es) |
MD (1) | MD3472157T2 (es) |
MX (3) | MX2018016281A (es) |
PE (2) | PE20240236A1 (es) |
PH (1) | PH12018502709A1 (es) |
PL (1) | PL3472157T3 (es) |
PT (1) | PT3472157T (es) |
RS (1) | RS64274B1 (es) |
SG (2) | SG10201912398PA (es) |
SI (1) | SI3472157T1 (es) |
TW (2) | TWI786050B (es) |
UA (2) | UA124106C2 (es) |
WO (1) | WO2017222977A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6243003B2 (ja) | 2013-03-15 | 2017-12-06 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Betタンパク質阻害剤としての三環式複素環 |
WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
DK3674302T3 (da) | 2014-04-23 | 2023-04-03 | Incyte Holdings Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner |
EP3194406B8 (en) | 2014-09-15 | 2021-03-31 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
KR102643344B1 (ko) * | 2016-06-20 | 2024-03-07 | 인사이트 코포레이션 | Bet 저해제의 결정질 고체 형태 |
TW202024078A (zh) * | 2018-09-13 | 2020-07-01 | 加拿大商增你智表觀遺傳學公司 | Bet溴結構域(bromodomain)抑制劑之固體形式之製備方法 |
US20230167166A1 (en) * | 2020-04-24 | 2023-06-01 | Memorial Sloan Kettering Cancer Center | Targeted therapy for the treatment & prevention of life-threatening complications of infection |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CA3184633A1 (en) | 2020-06-03 | 2021-12-09 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59170313A (ja) | 1983-03-14 | 1984-09-26 | Kurimoto Iron Works Ltd | スクリ−ンゲ−ト |
JPS6085739U (ja) | 1983-11-18 | 1985-06-13 | クラリオン株式会社 | テ−プレコ−ダにおけるピンチロ−ラ装置 |
JPH0314566A (ja) | 1989-06-09 | 1991-01-23 | Sankyo Co Ltd | ベンズイミダゾール誘導体 |
US5244912A (en) | 1991-03-28 | 1993-09-14 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof |
FR2710915B1 (fr) | 1993-10-04 | 1995-11-24 | Synthelabo | Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique. |
GB9410469D0 (en) | 1994-05-25 | 1994-07-13 | Erba Farmitalia | Imidazolylalkyl derivatives of imidazo (5,1-c) (1,4) benzoxazin-1-one and process for their preparation |
FR2731708B1 (fr) | 1995-03-13 | 1997-04-30 | Synthelabo | Derives de piperidine, leur procede de preparation et leur application en therapeutique |
FR2747678B1 (fr) | 1996-04-22 | 1998-05-22 | Synthelabo | Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique |
US6287693B1 (en) | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
NZ531171A (en) | 2000-04-21 | 2005-03-24 | Upjohn Co | Cabergoline-type compounds for treating fibromyalgia and chronic fatigue syndrome |
EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
FR2816619B1 (fr) | 2000-11-15 | 2003-01-31 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
CZ294493B6 (cs) | 2000-08-08 | 2005-01-12 | Sanofi-Synthelabo | Deriváty benzimidazolu, způsob jejich přípravy a léčebné prostředky s jejich obsahem |
US6919334B2 (en) | 2002-09-12 | 2005-07-19 | Wyeth | Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine |
AU2003293006A1 (en) | 2002-11-22 | 2004-06-18 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
EP1462103A1 (en) | 2003-03-25 | 2004-09-29 | Faust Pharmaceuticals | NO donors, combination products and uses as modulators of neurotransmitter release |
AU2005214258A1 (en) | 2004-02-23 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | Novel heterocyclic compound |
EP1732541A4 (en) | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
DE102005011058A1 (de) | 2005-03-10 | 2006-09-14 | Merck Patent Gmbh | Substituierte Tetrahydro-pyrrolo-chinolinderivate |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
US20080318999A1 (en) | 2005-08-05 | 2008-12-25 | Methvin Isaac | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators |
US8975259B2 (en) | 2007-04-27 | 2015-03-10 | University Of Rochester | Compositions and methods for inhibiting G protein signaling |
US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
WO2009020559A2 (en) | 2007-08-03 | 2009-02-12 | The J. David Gladstone Institutes | Agents that inhibit p-tefb interactions and methods of use thereof |
CA2710740C (en) | 2007-12-28 | 2016-07-19 | Shinji Miyoshi | Thienotriazolodiazepine compound as antitumor agent |
DE102008052618A1 (de) | 2008-10-21 | 2010-04-22 | Henkel Ag & Co. Kgaa | Tricyclische Aldehyde und C,H-acide Verbindungen |
US8669249B2 (en) | 2009-03-27 | 2014-03-11 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) polymerase (PARP) inhibitors |
TW201105681A (en) | 2009-06-10 | 2011-02-16 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
TW201103941A (en) | 2009-06-10 | 2011-02-01 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
WO2011024987A1 (ja) | 2009-08-31 | 2011-03-03 | 塩野義製薬株式会社 | 芳香族縮合へテロ環誘導体およびそれらを含有する医薬組成物 |
GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
ES2446647T3 (es) | 2009-11-05 | 2014-03-10 | Glaxosmithkline Llc | Inhibidor de bromodominio de benzodiazepina |
WO2011054845A1 (en) | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
EP2955524A3 (en) | 2009-11-05 | 2016-03-23 | GlaxoSmithKline LLC | Novel process |
GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
JP2013525366A (ja) | 2010-04-23 | 2013-06-20 | キネタ・インコーポレイテツド | 抗ウイルス性化合物 |
CN104311562B (zh) | 2010-05-14 | 2017-07-04 | 达那-法伯癌症研究所 | 用于治疗瘤形成、炎性疾病和其他失调的组合物和方法 |
CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
CN103119160B (zh) | 2010-05-14 | 2016-06-01 | 达那-法伯癌症研究所 | 用于调节代谢的组合物和方法 |
CN105582014B (zh) | 2010-05-14 | 2019-06-14 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
EP2585465B1 (en) | 2010-06-22 | 2014-11-12 | GlaxoSmithKline LLC | Benzotriazolodiazepine compounds inhibitors of bromodomains |
US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
KR20130116358A (ko) | 2011-02-09 | 2013-10-23 | 에프. 호프만-라 로슈 아게 | Pi3 키나아제 억제제로서 헤테로사이클릭 화합물 |
WO2012116170A1 (en) | 2011-02-23 | 2012-08-30 | Ming-Ming Zhou | Inhibitors of bromodomains as modulators of gene expression |
WO2012126901A1 (en) | 2011-03-21 | 2012-09-27 | F. Hoffmann-La Roche Ag | Benzoxazepin compounds selective for pi3k p110 delta and methods of use |
GB201106799D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
GB201106743D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2012178208A2 (en) | 2011-06-24 | 2012-12-27 | The Trustees Of The Stevens Institute Of Technology | Selective inhibitors of histone deacetylase isoform 6 and methods thereof |
JP2013010719A (ja) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途 |
AU2012290261A1 (en) | 2011-07-29 | 2014-02-20 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of HIV |
GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
KR101560073B1 (ko) | 2011-08-31 | 2015-10-13 | 오쓰까 세이야꾸 가부시키가이샤 | 퀴놀론 화합물 |
DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
EP2757887B1 (en) | 2011-09-22 | 2017-04-26 | VIIV Healthcare UK Limited | Pyrrolopyridinone compounds and methods for treating hiv |
CN103857391B (zh) | 2011-09-30 | 2016-06-08 | 沈阳蓝桑医药生物技术研发有限公司 | 含有瑞利格内酯的药物组合物及其应用 |
WO2013060636A1 (en) | 2011-10-25 | 2013-05-02 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
RS58911B1 (sr) | 2011-11-01 | 2019-08-30 | Resverlogix Corp | Oralne formulacije sa trenutnim otpuštanjem za supstituisane hinazolinone |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
US20150133434A1 (en) | 2012-03-28 | 2015-05-14 | The J. David Gladstone Institutes | Compositions and Methods for Reactivating Latent Immunodeficiency Virus |
US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
US20130281396A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
WO2013155695A1 (en) | 2012-04-20 | 2013-10-24 | Abbott Laboratories | Isoindolone derivatives |
TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
EP2864336B1 (en) | 2012-06-06 | 2016-11-23 | Constellation Pharmaceuticals, Inc. | Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof |
BR112014031068A2 (pt) | 2012-06-12 | 2017-06-27 | Abbvie Inc | derivados piridinona e piridazinona |
CN105050605A (zh) | 2012-06-25 | 2015-11-11 | 翁科埃蒂克斯股份公司 | 使用噻吩并三唑并二氮杂*化合物治疗淋巴瘤的方法 |
WO2014015175A1 (en) | 2012-07-18 | 2014-01-23 | Massachusetts Institute Of Technology | Compositions and methods for modulating brd4 bioactivity |
CN104755473B (zh) | 2012-08-16 | 2017-03-08 | 拜耳医药股份有限公司 | 2,3‑苯并二氮杂* |
EP2884983B1 (en) | 2012-08-16 | 2017-10-04 | GlaxoSmithKline LLC | Benzodiazepines for treating small cell lung cancer |
CN104781259B (zh) | 2012-09-28 | 2018-06-01 | 拜耳制药股份公司 | 抑制bet蛋白的5-芳基三唑并氮杂* |
WO2014068402A2 (en) | 2012-09-28 | 2014-05-08 | Oncoethix Sa | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
CN104854090B (zh) | 2012-11-09 | 2017-12-15 | 雅各布斯制药公司 | 杂芳基衍生物和其用途 |
US9422290B2 (en) | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
WO2014078257A1 (en) | 2012-11-14 | 2014-05-22 | Glaxosmithkline Llc | Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
US20160193206A1 (en) | 2012-12-20 | 2016-07-07 | Bayer Pharma Aktiengesellschaft | Bet-protein-inhibiting dihydropyridopyrazinones |
US20150344444A1 (en) | 2012-12-20 | 2015-12-03 | Bayer Pharma Aktiengesellschaft | Bet-protein-inhibiting dihydroxyquinoxalinones |
US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
WO2014128655A1 (en) | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
EP2961747B1 (en) | 2013-02-27 | 2017-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
BR112015022861A8 (pt) | 2013-03-11 | 2019-11-26 | Abbvie Inc | inibidores de bromodomínio |
TW201444843A (zh) | 2013-03-11 | 2014-12-01 | Abbvie Inc | 溴區結構域蛋白抑制劑 |
AU2014249192B2 (en) | 2013-03-11 | 2017-12-21 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
EP2970276A1 (en) | 2013-03-12 | 2016-01-20 | AbbVie Inc. | Dihydro-pyrrolopyridinone bromodomain inhibitors |
AU2014248647A1 (en) | 2013-03-12 | 2015-10-01 | Abbvie Inc. | Pyrrole amide inhibitors |
AU2014231563A1 (en) | 2013-03-12 | 2015-09-17 | Abbvie Inc. | Tetracyclic bromodomain inhibitors |
JP6280573B2 (ja) | 2013-03-14 | 2018-02-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | ブロモドメイン阻害薬としてのフロピリジン |
ES2915658T3 (es) | 2013-03-14 | 2022-06-24 | Glaxosmithkline Ip No 2 Ltd | Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolin-2,3-disustituida y su uso como inhibidores de bromodominio |
EA201591746A1 (ru) | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
US9714946B2 (en) | 2013-03-14 | 2017-07-25 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
JP2016519660A (ja) | 2013-03-15 | 2016-07-07 | エピジェネティクス・インコーポレイテッド | ブロモドメイン阻害剤としてのオキサゾロ[5,4−c]キノリン−2−オン化合物 |
EP2970265B1 (en) | 2013-03-15 | 2018-08-08 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
JP6243003B2 (ja) | 2013-03-15 | 2017-12-06 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Betタンパク質阻害剤としての三環式複素環 |
WO2014154762A1 (en) | 2013-03-27 | 2014-10-02 | Boehringer Ingelheim International Gmbh | Dihydroquinazolinone analogues as brd4 inhibitors |
US9102684B2 (en) | 2013-03-27 | 2015-08-11 | Boehringer Ingelheim International Gmbh | Indolinone analogues |
TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類 |
US10435364B2 (en) | 2013-04-17 | 2019-10-08 | Albert Ludwigs Universität Freiburg | Compounds for use as bromodomain inhibitors |
EP2989096B1 (en) | 2013-04-26 | 2019-04-10 | BeiGene, Ltd. | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones |
TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
JP6373978B2 (ja) | 2013-05-27 | 2018-08-15 | ノバルティス アーゲー | イミダゾピロリジノン誘導体および疾患の処置におけるその使用 |
US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
WO2014191911A1 (en) | 2013-05-28 | 2014-12-04 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
WO2014191906A1 (en) | 2013-05-28 | 2014-12-04 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
ITMI20130991A1 (it) | 2013-06-17 | 2014-12-18 | Industrie De Nora Spa | Sistema per la misurazione di correnti presenti sugli elettrodi in celle elettrolitiche interconnesse. |
WO2014202578A1 (de) | 2013-06-17 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituierte phenyl-2,3-benzodiazepine |
JP6599852B2 (ja) | 2013-06-21 | 2019-10-30 | ゼニス・エピジェネティクス・リミテッド | ブロモドメイン阻害剤としての新規の置換された二環式化合物 |
WO2015002754A2 (en) | 2013-06-21 | 2015-01-08 | Zenith Epigenetics Corp. | Novel bicyclic bromodomain inhibitors |
AR096758A1 (es) * | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
MX2015017963A (es) | 2013-06-28 | 2016-11-10 | Abbvie Inc | Inhibidores de bromodominio. |
CA2917319A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
CN105555779B (zh) | 2013-07-16 | 2019-05-10 | 巴斯夫欧洲公司 | 除草的嗪类 |
WO2015013635A2 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
KR101672096B1 (ko) | 2013-09-30 | 2016-11-02 | 주식회사 엘지화학 | 헤테로환 화합물 및 이를 포함하는 유기 발광 소자 |
EP3640241B1 (en) | 2013-10-18 | 2022-09-28 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
WO2015081246A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
EP3089970B1 (en) | 2013-12-09 | 2018-10-17 | AbbVie Inc. | Dihydropyridinone and dihydropyridazinone derivatives useful as bromodomain inhibitors |
WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
EP3083559B1 (en) * | 2013-12-20 | 2021-03-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
SI3092227T1 (sl) | 2014-01-09 | 2018-10-30 | Orion Corporation | Biciklični heterociklični derivati kot zaviralci bromodomaina |
WO2015131005A1 (en) | 2014-02-28 | 2015-09-03 | The Regents Of The University Of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
DK3674302T3 (da) | 2014-04-23 | 2023-04-03 | Incyte Holdings Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner |
EA201692129A1 (ru) | 2014-04-23 | 2017-03-31 | Басф Се | Диаминотриазины в качестве гербицидов |
CA2946519C (en) | 2014-04-23 | 2022-07-19 | Takeda Pharmaceutical Company Limited | Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease |
EP3137085A4 (en) | 2014-05-02 | 2017-12-27 | Oncoethix GmbH | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
JP2017514907A (ja) | 2014-05-02 | 2017-06-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いる耐性非ホジキンリンパ腫、髄芽腫及び/又はalk+非小細胞肺癌の治療方法 |
WO2015169953A1 (en) | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating glioma using thienotriazolodiazepine compounds |
JP2017519727A (ja) | 2014-05-08 | 2017-07-20 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法 |
WO2015184257A2 (en) | 2014-05-30 | 2015-12-03 | Icahn School Of Medicine At Mount Sinai | Small molecule transcription modulators of bromodomains |
PT3157928T (pt) | 2014-06-20 | 2019-05-30 | Constellation Pharmaceuticals Inc | Formas cristalinas de 2-((4s)-6-(4-clorofenil)-1-metil-4h-benzo[c] isoxazolo[4,5-e]azepin-4-il)acetamida |
US9861077B2 (en) | 2014-07-11 | 2018-01-09 | Jaan Aked-Hurditch | Leash accessory |
EP3194406B8 (en) | 2014-09-15 | 2021-03-31 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
LT3461821T (lt) | 2014-10-24 | 2020-08-10 | Bristol-Myers Squibb Company | Indolo karboksamido junginiai, naudotini kaip kinazės inhibitoriai |
MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
CA2974153A1 (en) | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins |
WO2016186453A1 (en) | 2015-05-20 | 2016-11-24 | Kainos Medicine, Inc. | Quinoline derivatives as bromodomain inhibitors |
CA2987384A1 (en) | 2015-05-29 | 2016-12-08 | Shionogi & Co., Ltd. | Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity |
CN105039258B (zh) | 2015-07-03 | 2018-04-17 | 北京大学 | 将非神经元细胞重编程为神经元样细胞的方法和组合物 |
TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
CN105254635A (zh) | 2015-10-30 | 2016-01-20 | 中国药科大学 | 一类咪唑并吡嗪类化合物及其药物组合物和用途 |
US20170127985A1 (en) | 2015-11-11 | 2017-05-11 | Medtronic Minimed, Inc. | Sensor set |
CA3007168A1 (en) | 2015-12-14 | 2017-06-22 | Zenith Epigenetics Ltd. | 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors |
US10519151B2 (en) | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
EP3412669A4 (en) | 2016-02-05 | 2019-09-04 | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd | TRICYCLIC COMPOUND FOR PROTEIN INHIBITOR CONTAINING BROMODOMAINE AND PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
KR102643344B1 (ko) | 2016-06-20 | 2024-03-07 | 인사이트 코포레이션 | Bet 저해제의 결정질 고체 형태 |
CN108069958A (zh) | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
-
2017
- 2017-06-19 KR KR1020227036514A patent/KR102643344B1/ko active IP Right Grant
- 2017-06-19 EP EP17734590.7A patent/EP3472157B1/en active Active
- 2017-06-19 HU HUE17734590A patent/HUE062234T2/hu unknown
- 2017-06-19 RS RS20230430A patent/RS64274B1/sr unknown
- 2017-06-19 ES ES17734590T patent/ES2945063T3/es active Active
- 2017-06-19 WO PCT/US2017/038121 patent/WO2017222977A1/en unknown
- 2017-06-19 US US15/626,539 patent/US10189832B2/en active Active
- 2017-06-19 PL PL17734590.7T patent/PL3472157T3/pl unknown
- 2017-06-19 BR BR112018076486-8A patent/BR112018076486A2/pt unknown
- 2017-06-19 CN CN202111446313.6A patent/CN114369091A/zh active Pending
- 2017-06-19 IL IL263824A patent/IL263824B2/en unknown
- 2017-06-19 AU AU2017281286A patent/AU2017281286B2/en active Active
- 2017-06-19 SG SG10201912398PA patent/SG10201912398PA/en unknown
- 2017-06-19 TW TW106120412A patent/TWI786050B/zh active
- 2017-06-19 CR CR20220651A patent/CR20220651A/es unknown
- 2017-06-19 CN CN202111443358.8A patent/CN114366748A/zh active Pending
- 2017-06-19 PT PT177345907T patent/PT3472157T/pt unknown
- 2017-06-19 CA CA3028689A patent/CA3028689A1/en active Pending
- 2017-06-19 CN CN201780038099.6A patent/CN109715625B/zh active Active
- 2017-06-19 JP JP2018566525A patent/JP7096170B2/ja active Active
- 2017-06-19 KR KR1020197001805A patent/KR102460046B1/ko active IP Right Grant
- 2017-06-19 MD MDE20190507T patent/MD3472157T2/ro unknown
- 2017-06-19 UA UAA201900524A patent/UA124106C2/uk unknown
- 2017-06-19 SG SG11201811416VA patent/SG11201811416VA/en unknown
- 2017-06-19 DK DK17734590.7T patent/DK3472157T3/da active
- 2017-06-19 CR CR20190027A patent/CR20190027A/es unknown
- 2017-06-19 CA CA3220975A patent/CA3220975A1/en active Pending
- 2017-06-19 CA CA3220957A patent/CA3220957A1/en active Pending
- 2017-06-19 SI SI201731358T patent/SI3472157T1/sl unknown
- 2017-06-19 LT LTEPPCT/US2017/038121T patent/LT3472157T/lt unknown
- 2017-06-19 FI FIEP17734590.7T patent/FI3472157T3/fi active
- 2017-06-19 KR KR1020247006758A patent/KR20240033293A/ko active Application Filing
- 2017-06-19 PE PE2023002468A patent/PE20240236A1/es unknown
- 2017-06-19 IL IL302528A patent/IL302528A/en unknown
- 2017-06-19 TW TW111147670A patent/TWI830533B/zh active
- 2017-06-19 MX MX2018016281A patent/MX2018016281A/es unknown
- 2017-06-19 PE PE2018003269A patent/PE20190623A1/es unknown
- 2017-06-19 EP EP23160938.9A patent/EP4234554A3/en active Pending
- 2017-06-19 UA UAA202008134A patent/UA125476C2/uk unknown
- 2017-06-19 HR HRP20230466TT patent/HRP20230466T1/hr unknown
-
2018
- 2018-12-07 US US16/213,202 patent/US10626114B2/en active Active
- 2018-12-19 CL CL2018003702A patent/CL2018003702A1/es unknown
- 2018-12-19 MX MX2021009776A patent/MX2021009776A/es unknown
- 2018-12-19 MX MX2023009524A patent/MX2023009524A/es unknown
- 2018-12-20 PH PH12018502709A patent/PH12018502709A1/en unknown
- 2018-12-28 CO CONC2018/0014339A patent/CO2018014339A2/es unknown
-
2019
- 2019-01-10 EC ECSENADI20191982A patent/ECSP19001982A/es unknown
-
2020
- 2020-02-19 CL CL2020000408A patent/CL2020000408A1/es unknown
- 2020-02-19 CL CL2020000407A patent/CL2020000407A1/es unknown
- 2020-03-24 US US16/828,031 patent/US11091480B2/en active Active
- 2020-12-18 US US17/127,351 patent/US11377446B2/en active Active
-
2021
- 2021-08-09 AU AU2021215112A patent/AU2021215112B2/en active Active
- 2021-08-17 IL IL285686A patent/IL285686B/en unknown
-
2022
- 2022-03-29 JP JP2022053417A patent/JP7375082B2/ja active Active
- 2022-06-02 US US17/830,494 patent/US20220306628A1/en active Pending
- 2022-07-01 JP JP2022107131A patent/JP2022130666A/ja active Pending
-
2023
- 2023-06-15 CY CY20231100282T patent/CY1126092T1/el unknown
- 2023-09-11 AU AU2023229471A patent/AU2023229471A1/en active Pending
- 2023-10-25 JP JP2023183248A patent/JP2024012372A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20190623A1 (es) | Formas solidas cristalinas de un inhibidor de bet | |
CY1126052T1 (el) | 1η-πυρρολο[2,3-c]πυριδιν-7(6η)-ονες και πυραζολο[3,4-c]πυριδιν-7(6η)- ονες ως αναστολεις των bet πρωτεϊνων | |
PH12019502318A1 (en) | Trycyclic heterocycles as bet protein inhibitors | |
CL2017000885A1 (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos | |
CL2016001629A1 (es) | Compuestos tricíclicos como agentes anticancerígenos | |
UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
CL2014003444A1 (es) | Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes. | |
NI201400125A (es) | Antagonistas de st2l y métodos de uso | |
JOP20140141B1 (ar) | استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية | |
CR20200276A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059) | |
UY34977A (es) | 2,3-benzodiazepinas | |
CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
DOP2014000255A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
CR20150426A (es) | 2,3-benzodiazepinas biciclo y espirocíclico sustituidas | |
MX2015014181A (es) | 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer. | |
TW201613935A (en) | Tricyclic heterocycles as BET protein inhibitors | |
DOP2016000064A (es) | Derivados de fenilalanina sustituidos | |
BR112012023836A2 (pt) | composto tricíclicos e inibidores de pbk contendo os mesmos | |
PE20191134A1 (es) | Composiciones y metodos relacionados con agonistas de piridinoilpiperidina 5-ht1f | |
UY37139A (es) | Monotartrato de vinorelbina y su uso farmacéutico | |
CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores | |
AR093874A1 (es) | Composicion para control de malezas |